UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Blood, 2019-07, Vol.134 (2), p.123-133

2019

Volltextzugriff (PDF)

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

CPT: pharmacometrics and systems pharmacology, 2020-11, Vol.9 (11), p.649-658

2020

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Volltextzugriff (PDF)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Blood cancer journal (New York), 2021-05, Vol.11 (5), p.89-5, Article 89

2021

Volltextzugriff (PDF)

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

BMC cancer, 2013-10, Vol.13 (1), p.460-460, Article 460

2013

Volltextzugriff (PDF)

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Journal of the American Society of Nephrology, 2024-03, Vol.35 (3), p.347-360

2024

Volltextzugriff (PDF)

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.1846-1858

2023

Volltextzugriff (PDF)

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

British journal of clinical pharmacology, 2022-05, Vol.88 (5), p.2052-2064

2022

Volltextzugriff (PDF)

Preclinical profile of cabazitaxel

Drug design, development and therapy, 2014-01, Vol.8 (default), p.1851-1867

2014

Volltextzugriff (PDF)

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

CPT: pharmacometrics and systems pharmacology, 2021-08, Vol.10 (8), p.928-940

2021

Volltextzugriff (PDF)

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2013-03, Vol.71 (3), p.681-692

2013

Volltextzugriff (PDF)

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

CPT: pharmacometrics and systems pharmacology, 2022-06, Vol.11 (6), p.766-777

2022

Volltextzugriff (PDF)

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

Clinical cancer research, 2013-06, Vol.19 (11), p.2973-2983

2013

Volltextzugriff (PDF)

Abstract 1372: Model based approach to evaluate Isatuximab (Isa) monthly dosing regimen in relapsed/refractory multiple myeloma (RRMM)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1372-1372

2021

Volltextzugriff (PDF)

Model Based Approach to Evaluate Isatuximab Monthly Dosing Regimen in Relapsed/Refractory Multiple Myeloma Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.44-44

2020

Volltextzugriff (PDF)

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Blood, 2022-11, Vol.140 (Supplement 1), p.4412-4414

2022

Volltextzugriff (PDF)

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8025-8025

2022

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors

Journal of clinical oncology, 2005-02, Vol.23 (4), p.889-898

2005

Volltextzugriff (PDF)

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2744-2744

2021

Volltextzugriff (PDF)

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Leukemia, 2021-02, Vol.35 (2), p.562-572

2021

Volltextzugriff (PDF)

P-306 Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S206-S207

2023

Volltextzugriff (PDF)

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.1897-1897

2019

Volltextzugriff (PDF)

Poster: MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S179

2022

Volltextzugriff (PDF)

MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S404-S405

2022

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(35)
Buchkapitel
(1)

Sprache

Englisch
(36)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(17)
Female
(12)
Pharmacology & Pharmacy
(12)
Male
(10)
Middle Aged
(10)
Oncology
(10)
Aged
(9)
Adult
(8)
Neoplasms - Drug Therapy
(8)
Tumors
(7)
Biological And Medical Sciences
(6)
Cabazitaxel
(6)
Medical Sciences
(6)
Multiple Myeloma - Drug Therapy
(6)
Pharmacokinetics
(6)
Aged, 80 And Over
(5)
Antineoplastic Agents - Pharmacokinetics
(5)
Drug Dosages
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1‑{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3‑b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

Preclinical profile of cabazitaxel

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

Abstract 1372: Model based approach to evaluate Isatuximab (Isa) monthly dosing regimen in relapsed/refractory multiple myeloma (RRMM)

Model Based Approach to Evaluate Isatuximab Monthly Dosing Regimen in Relapsed/Refractory Multiple Myeloma Patients

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

P-306 Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Poster: MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results

MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results

Suchergebnisse filtern